Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study1

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control

(2013) Helena Rodbard et al.   Endocrine Practice

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study

(2011) R. Gomis et al.   DIABETES OBESITY & METABOLISM

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

(2010) A. J. Scheen   DIABETES OBESITY & METABOLISM

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

(2010) M.-R. Taskinen et al.   DIABETES OBESITY & METABOLISM

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

(2010) S. Del Prato et al.   DIABETES OBESITY & METABOLISM

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes

(2010) T. Forst et al.   DIABETIC MEDICINE

Relationship of baseline HbA1cand efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

(2010) R. A. DeFronzo et al.   DIABETIC MEDICINE

The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans

(2010) S. Blech et al.   DRUG METABOLISM AND DISPOSITION

Improved Glycemic Control with Insulin Glargine Versus Pioglitazone as Add-On Therapy to Sulfonylurea or Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus

(2010) Luigi Meneghini et al.   Endocrine Practice

Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356) - investigations in DPP-4 deficient and wildtype rats

(2009) Silke Retlich et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus

(2009) L. BLONDE   CLEVELAND CLINIC JOURNAL OF MEDICINE

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

(2009) J. Rosenstock et al.   CURRENT MEDICAL RESEARCH AND OPINION

Incretin-Based Therapies: Viewpoints on the way to consensus

(2009) Michael. A. Nauck et al.   DIABETES CARE

Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18)

(2009) A. J. Scheen et al.   DIABETIC MEDICINE

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

(2009) D. Russell-Jones et al.   DIABETOLOGIA

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

(2009) Carolyn F Deacon et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors

(2009) Joshua J. Neumiller   JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION

Overview of the Gliptin Class (Dipeptidyl Peptidase-4 Inhibitors) in Clinical Practice

(2009) Nancy Bohannon   POSTGRADUATE MEDICINE

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Robust improvements in fasting and prandial measures of β-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database

(2008) R. E. Pratley et al.   DIABETES OBESITY & METABOLISM

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers

(2008) S. Hüttner et al.   JOURNAL OF CLINICAL PHARMACOLOGY

(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors

(2008) L. Thomas et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS